Table 11.6f

Immunosuppression Use for Maintenance by Regimen

One Year Following Transplantation, 1995 to 2004

Recipients with Heart Transplants

  Transplant Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 2,363 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057 2,016
Functioning Graft at 1 Year PostTx 1,907 1,932 1,876 1,939 1,780 1,820 1,851 1,820 1,754 1,718
With Maintenance Use Recorded at 1 Year PostTx 145 168 221 1,083 1,724 1,756 1,830 1,785 1,717 1,709
--- + MMF/MPA 0.7% 0.6% 0.9% 0.2% 0.1% 0.2% 0.1% 0.2% 0.4% 0.2%
--- + MMF/MPA + Other Antimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.2% 0.2%
--- + MMF/MPA + Steroids 0.0% 0.0% 0.5% 0.6% 0.5% 0.8% 0.5% 0.6% 0.3% 0.6%
--- + Other Antimet 1.4% 0.0% 0.0% 0.2% 0.2% 0.2% 0.1% 0.0% 0.1% 0.0%
--- + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1%
--- + Other Antimet + Steroids 0.0% 0.6% 0.0% 0.1% 0.1% 0.1% 0.2% 0.1% 0.1% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.1% 0.0% 0.2% 0.0%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.4% 0.3% 0.2% 0.1%
--- + Steroids 4.1% 3.0% 4.5% 5.4% 2.0% 2.2% 3.4% 0.4% 0.2% 0.4%
CyA 3.4% 0.6% 0.9% 1.0% 0.9% 1.3% 0.8% 0.8% 0.8% 0.3%
CyA + MMF/MPA 0.0% 2.4% 5.9% 7.6% 8.5% 9.7% 9.0% 8.6% 8.5% 8.5%
CyA + MMF/MPA + Other Antimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.1%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% 0.5% 0.1%
CyA + MMF/MPA + Steroids 2.1% 21.4% 26.7% 36.4% 35.1% 40.9% 33.5% 27.6% 24.9% 23.5%
CyA + Other Antimet 6.9% 7.7% 3.2% 3.6% 3.3% 2.3% 1.6% 2.4% 1.2% 1.4%
CyA + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.1%
CyA + Other Antimet + Steroids 35.9% 32.1% 23.1% 15.1% 11.3% 6.6% 4.6% 3.2% 2.0% 2.7%
CyA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.2% 0.8% 0.8% 0.5%
CyA + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.2% 1.2% 1.3% 0.8% 1.2% 2.5% 1.1%
CyA + Steroids 4.1% 4.8% 4.5% 2.6% 4.9% 3.6% 1.9% 1.9% 1.9% 0.9%
Tac 0.0% 1.8% 2.3% 1.2% 1.3% 1.1% 0.7% 1.6% 1.3% 1.2%
Tac + MMF/MPA 0.0% 0.6% 0.5% 2.2% 2.8% 3.4% 6.9% 6.3% 10.4% 10.8%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.3% 0.2% 0.3%
Tac + MMF/MPA + Steroids 0.0% 2.4% 8.6% 13.9% 14.6% 17.0% 21.2% 25.0% 25.6% 32.1%
Tac + Other Antimet 0.0% 1.2% 0.0% 0.5% 0.9% 0.9% 0.9% 1.1% 1.0% 1.3%
Tac + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.1%
Tac + Other Antimet + Steroids 6.2% 3.6% 6.3% 4.2% 3.4% 1.9% 2.6% 1.9% 2.1% 1.5%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 1.3% 1.5% 0.9%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.3% 0.5% 1.0% 2.9% 4.5% 4.4% 2.1%
Tac + Steroids 2.8% 2.4% 3.2% 2.4% 2.3% 2.3% 4.3% 3.5% 3.0% 2.6%
Other Regimen 32.4% 14.9% 8.6% 2.6% 5.9% 2.7% 3.1% 6.0% 5.5% 6.3%


Source: OPTN/SRTR Data as of May 1, 2006.

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; Other Antimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.